JP5247675B2 - 造血性幹細胞の増殖を調節する方法 - Google Patents

造血性幹細胞の増殖を調節する方法 Download PDF

Info

Publication number
JP5247675B2
JP5247675B2 JP2009501606A JP2009501606A JP5247675B2 JP 5247675 B2 JP5247675 B2 JP 5247675B2 JP 2009501606 A JP2009501606 A JP 2009501606A JP 2009501606 A JP2009501606 A JP 2009501606A JP 5247675 B2 JP5247675 B2 JP 5247675B2
Authority
JP
Japan
Prior art keywords
hsc
pge
cells
pge2
agm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009501606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530408A (ja
JP2009530408A5 (enExample
Inventor
レオナード アイ． ゾン
トリスタ イー． ノース
ウォルフラム ゴエスリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2009530408A publication Critical patent/JP2009530408A/ja
Publication of JP2009530408A5 publication Critical patent/JP2009530408A5/ja
Application granted granted Critical
Publication of JP5247675B2 publication Critical patent/JP5247675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Materials For Medical Uses (AREA)
JP2009501606A 2006-03-24 2007-03-26 造血性幹細胞の増殖を調節する方法 Active JP5247675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78596806P 2006-03-24 2006-03-24
US60/785,968 2006-03-24
PCT/US2007/007419 WO2007112084A2 (en) 2006-03-24 2007-03-26 Method to modulate hematopoietic stem cell growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013046473A Division JP6041711B2 (ja) 2006-03-24 2013-03-08 造血性幹細胞の増殖を調節する方法

Publications (3)

Publication Number Publication Date
JP2009530408A JP2009530408A (ja) 2009-08-27
JP2009530408A5 JP2009530408A5 (enExample) 2010-04-15
JP5247675B2 true JP5247675B2 (ja) 2013-07-24

Family

ID=38526581

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2009501606A Active JP5247675B2 (ja) 2006-03-24 2007-03-26 造血性幹細胞の増殖を調節する方法
JP2013046473A Expired - Fee Related JP6041711B2 (ja) 2006-03-24 2013-03-08 造血性幹細胞の増殖を調節する方法
JP2015147317A Active JP6208719B2 (ja) 2006-03-24 2015-07-27 造血性幹細胞の増殖を調節する方法
JP2016175313A Expired - Fee Related JP6530732B2 (ja) 2006-03-24 2016-09-08 造血性幹細胞の増殖を調節する方法
JP2019027038A Expired - Fee Related JP6797222B2 (ja) 2006-03-24 2019-02-19 造血性幹細胞の増殖を調節する方法
JP2019171346A Withdrawn JP2019214620A (ja) 2006-03-24 2019-09-20 造血性幹細胞の増殖を調節する方法
JP2021170835A Pending JP2022025091A (ja) 2006-03-24 2021-10-19 造血性幹細胞の増殖を調節する方法
JP2023098876A Pending JP2023112027A (ja) 2006-03-24 2023-06-16 造血性幹細胞の増殖を調節する方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013046473A Expired - Fee Related JP6041711B2 (ja) 2006-03-24 2013-03-08 造血性幹細胞の増殖を調節する方法
JP2015147317A Active JP6208719B2 (ja) 2006-03-24 2015-07-27 造血性幹細胞の増殖を調節する方法
JP2016175313A Expired - Fee Related JP6530732B2 (ja) 2006-03-24 2016-09-08 造血性幹細胞の増殖を調節する方法
JP2019027038A Expired - Fee Related JP6797222B2 (ja) 2006-03-24 2019-02-19 造血性幹細胞の増殖を調節する方法
JP2019171346A Withdrawn JP2019214620A (ja) 2006-03-24 2019-09-20 造血性幹細胞の増殖を調節する方法
JP2021170835A Pending JP2022025091A (ja) 2006-03-24 2021-10-19 造血性幹細胞の増殖を調節する方法
JP2023098876A Pending JP2023112027A (ja) 2006-03-24 2023-06-16 造血性幹細胞の増殖を調節する方法

Country Status (10)

Country Link
US (7) US8168428B2 (enExample)
EP (3) EP2423303A1 (enExample)
JP (8) JP5247675B2 (enExample)
CN (2) CN102626517B (enExample)
AU (1) AU2007230902B2 (enExample)
CA (1) CA2647201C (enExample)
MX (3) MX373998B (enExample)
RU (2) RU2425876C2 (enExample)
WO (1) WO2007112084A2 (enExample)
ZA (2) ZA200808123B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013155175A (ja) * 2006-03-24 2013-08-15 Childrens Medical Center Corp 造血性幹細胞の増殖を調節する方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5426389B2 (ja) 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション 組織の再生を亢進するための方法
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
US8263403B2 (en) * 2007-04-23 2012-09-11 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
ITUD20080058A1 (it) 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
CN107523587A (zh) 2008-11-06 2017-12-29 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20120202288A1 (en) * 2009-03-19 2012-08-09 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20120195862A1 (en) * 2009-04-17 2012-08-02 Children's Medical Center Corporation Biomechanical induction of hematopoiesis
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
JP6037836B2 (ja) * 2009-11-15 2016-12-07 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 特異的プロスタグランジンｅ２受容体の特定を含む幹細胞の送達及び生着を高めるための方法
US20130129686A1 (en) * 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
WO2011143125A2 (en) * 2010-05-10 2011-11-17 Fate Therapeutics, Inc. Biovessels
CN112501118A (zh) * 2010-08-12 2021-03-16 菲特治疗公司 改进的造血干细胞和祖细胞疗法
DK2663313T3 (en) * 2011-01-13 2018-11-26 Scipharm S A R L PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
EP2701694A4 (en) * 2011-04-28 2014-10-08 Univ Duke METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
CN108220246B (zh) 2011-09-30 2022-07-12 蓝鸟生物公司 用于改善病毒转导的化合物
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
WO2013086029A1 (en) 2011-12-05 2013-06-13 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
WO2014081760A1 (en) 2012-11-20 2014-05-30 Duke University Methods of treating hemoglobinopathies
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP2968416A4 (en) 2013-03-15 2016-08-17 Fate Therapeutics Inc CELL POTENTIAL TEST FOR THERAPEUTIC POTENTIAL
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
EP3134096A4 (en) * 2014-04-23 2018-01-10 Texas Heart Institute Methods of enhancing stem cell engraftment
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US10435677B2 (en) 2014-09-16 2019-10-08 Sangamo Therapeutics, Inc. Genetically modified human cell with a corrected mutant sickle cell mutation
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2016296741A1 (en) 2015-07-21 2018-02-22 The Children's Medical Center Corporation PD-L1 expressing hematopoietic stem cells and uses
CN105296427A (zh) * 2015-10-23 2016-02-03 深圳爱生再生医学科技有限公司 造血干细胞的体外扩增培养方法
WO2017073692A1 (ja) * 2015-10-30 2017-05-04 国立大学法人鳥取大学 メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬
JP7534070B2 (ja) 2015-11-04 2024-08-14 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
BR112018016450A2 (pt) 2016-02-12 2018-12-26 Bluebird Bio Inc composições intensificadoras de vcn e métodos de uso das mesmas
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
CA3014667A1 (en) * 2016-03-04 2017-09-08 The Board Of Trustees Of Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
TWI719315B (zh) * 2017-06-07 2021-02-21 中央研究院 移除未分化的萬能性幹細胞之方法
CN111212648B (zh) 2017-06-09 2024-07-09 莱兰斯坦福初级大学评议会 用于预防或治疗肌肉疾患的组合物和方法
EP3672590B1 (en) * 2017-08-22 2025-02-12 The Children's Medical Center Corporation Methods for inducing hematopoietic stem cell specificity
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
JP7416700B2 (ja) 2017-11-14 2024-01-17 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
EP3597211A1 (en) 2018-07-19 2020-01-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Periostin compounds for the treatment of haematological complications
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
US20220127576A1 (en) * 2019-02-13 2022-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for stem cell therapy
CN110051839A (zh) * 2019-04-16 2019-07-26 诺航生物技术(徐州)有限公司 一种促进脐带血干细胞体外扩增和增强脐带血干细胞移植后造血重建功能的药物
FI130749B1 (en) * 2020-01-24 2024-02-26 Faron Pharmaceuticals Oy USE OF VAP-1 INHIBITOR IN THE EX VIVO CULTURE OF HEMATOPOEITIC STEM CELLS AND IN THE TREATMENT OF BONE Marrow Loss or BONE Marrow Dysfunction
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11883436B2 (en) 2020-08-17 2024-01-30 The Board Of Trustees Of The University Of Illinois Method of preparing hematopoietic stem and progenitor cells for transplantation
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
KR20240136869A (ko) 2023-03-07 2024-09-19 인제대학교 산학협력단 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA103846A (en) 1906-12-03 1907-02-26 William Bell Manufacture of half-tone printing blocks
US3217903A (en) 1961-01-19 1965-11-16 Mc Graw Edison Co Segregating control
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4239679A (en) 1979-06-27 1980-12-16 Diamond Shamrock Corporation High bulk density rigid poly(vinyl chloride) resin powder composition and preparation thereof
HU181154B (en) 1980-07-18 1983-06-28 Epitestudomanyi Intezet Shaped building unit and space limiting or dividing structure made of same as well as method for producing the shaped building unit
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
SG59931A1 (en) * 1989-10-16 1999-02-22 Amgen Inc Stem cell factor
US5114672A (en) 1990-08-27 1992-05-19 Cryo-Cell International, Inc. Method for preserving blood fluid
AU702871B2 (en) * 1993-08-23 1999-03-11 Nexell Therapeutics Inc. (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
AU6125396A (en) * 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
RU2259830C2 (ru) 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
US6226997B1 (en) 1999-12-07 2001-05-08 Cryo-Cell International, Inc. Method and device for maintaining temperature integrity of cryogenically preserved biological samples
US6852534B2 (en) 2000-11-03 2005-02-08 Kourion Therapeutics Gmbh Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
JP4077158B2 (ja) 2001-01-10 2008-04-16 株式会社メニコン 植物性繊維分解剤およびそれを用いた植物性廃棄物の処理法
MXPA03007175A (es) 2001-02-14 2005-02-14 Anthrogenesis Corp Placenta de mamiferos postparto, su uso y celulas madres placentales extraidas de ella.
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
WO2003042405A2 (en) 2001-11-15 2003-05-22 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
WO2003055989A2 (en) * 2001-12-21 2003-07-10 Mount Sinai Hospital Cellular compositions and methods of making and using them
RU2205627C1 (ru) * 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
JP4497320B2 (ja) 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
WO2004078169A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
EP1613742A2 (en) 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2006005153A1 (en) * 2004-07-09 2006-01-19 Bc Cancer Agency Nup98-hox fusions for expansion of hemopoietic stem cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
CA2597757C (en) 2005-02-10 2016-06-28 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
WO2007117262A2 (en) 2005-07-29 2007-10-18 Athersys, Inc. Culture of non-embryonic cells at high cell density
JP4562618B2 (ja) 2005-08-18 2010-10-13 陽一 佐藤 空き缶処理車
US8318489B2 (en) * 2005-12-22 2012-11-27 Bruce Paul Davidson Prostacyclin directed differentiation of cardiomyocytes from human embryonic stem cells
MX373998B (es) 2006-03-24 2020-07-22 Childrens Medical Center Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc.
US8241903B2 (en) 2006-06-22 2012-08-14 Yeda Research And Development Co., Ltd. Catecholamine receptor modulation
WO2008021475A2 (en) 2006-08-16 2008-02-21 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
KR20080042761A (ko) 2006-11-10 2008-05-15 문찬일 렙틴을 이용한 줄기세포 증식방법
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013155175A (ja) * 2006-03-24 2013-08-15 Childrens Medical Center Corp 造血性幹細胞の増殖を調節する方法

Also Published As

Publication number Publication date
US10272110B2 (en) 2019-04-30
US20090285786A1 (en) 2009-11-19
JP2019094347A (ja) 2019-06-20
US20120189594A1 (en) 2012-07-26
ZA200808123B (en) 2010-03-31
JP2022025091A (ja) 2022-02-09
JP2019214620A (ja) 2019-12-19
AU2007230902A1 (en) 2007-10-04
JP2023112027A (ja) 2023-08-10
EP2423303A1 (en) 2012-02-29
JP2015232010A (ja) 2015-12-24
US9028811B2 (en) 2015-05-12
RU2011115827A (ru) 2012-10-27
AU2007230902B2 (en) 2013-03-14
US20130216507A1 (en) 2013-08-22
CA2647201A1 (en) 2007-10-04
JP6041711B2 (ja) 2016-12-14
JP6208719B2 (ja) 2017-10-04
CN102626517A (zh) 2012-08-08
CA2647201C (en) 2016-03-08
US20120189593A1 (en) 2012-07-26
US20130209423A1 (en) 2013-08-15
RU2493252C2 (ru) 2013-09-20
CN101495623B (zh) 2013-09-11
US8168428B2 (en) 2012-05-01
MX373998B (es) 2020-07-22
WO2007112084A2 (en) 2007-10-04
EP3424507A1 (en) 2019-01-09
JP2016210802A (ja) 2016-12-15
US8551782B2 (en) 2013-10-08
WO2007112084A8 (en) 2008-11-20
CN102626517B (zh) 2015-07-29
WO2007112084A3 (en) 2009-01-08
JP6797222B2 (ja) 2020-12-09
JP2013155175A (ja) 2013-08-15
JP6530732B2 (ja) 2019-06-12
AU2007230902A8 (en) 2009-07-23
JP2009530408A (ja) 2009-08-27
HK1173948A1 (en) 2013-05-31
MX2019007494A (es) 2019-09-06
US8563310B2 (en) 2013-10-22
EP1999255A2 (en) 2008-12-10
US10278990B2 (en) 2019-05-07
RU2425876C2 (ru) 2011-08-10
RU2008142106A (ru) 2010-04-27
MX2008012178A (es) 2009-01-23
WO2007112084A9 (en) 2007-11-22
ZA200906574B (en) 2010-06-30
US20120189592A1 (en) 2012-07-26
US20130209424A1 (en) 2013-08-15
CN101495623A (zh) 2009-07-29

Similar Documents

Publication Publication Date Title
JP6797222B2 (ja) 造血性幹細胞の増殖を調節する方法
AU2019201235B2 (en) Method to modulate hematopoietic stem cell growth
AU2013202353B2 (en) Method to modulate hematopoietic stem cell growth
HK40002933A (en) Method to modulate hematopoietic stem cell growth
HK1164363A (en) Method to modulate hematopoietic stem cell growth

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130409

R150 Certificate of patent or registration of utility model

Ref document number: 5247675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160419

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250